Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …

Background Issues concerning the potential risks of reactivating chronic hepatitis B virus
arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients …

Introduction Tumour necrosis factor (TNF)‐α antagonists are effective for the treatment of
plaque‐type psoriasis and psoriatic arthritis, but concerns remain about the safety of these …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Background Tumor necrosis factor inhibitory agents are currently considered to be
contraindicated in psoriatic patients with hepatitis B. Objective We aim to provide guidance …

Tumor necrosis factor-alpha (TNF-α) inhibitors represent an effective treatment for severe
psoriasis in hepatitis C virus (HCV) patients. The literature reports mainly on short-term …

The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …

Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make
patients more susceptible to viral, bacterial, and fungal infections because of their …

Introduction: Biologics are highly effective, important treatment options for moderate-to-
severe psoriasis. Biologics are well tolerated and have few side effects. However, the use of …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …